Amylyx Pharmaceuticals (AMLX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Amylyx Pharmaceuticals

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$32.63-0.52(-0.02%)Pre-market

Market Cap

$3.77B

P/B

15.8x

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

How this company scores

WeakMetricSide Score: 37/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (6/25).

Profitability8/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 20.2x5y range 20.2x – 672.3x

P/S · 501.4x5y range 0.4x – 501.4x

Currently above its 10-quarter median.

P/B · 15.8x5y range 0.5x – 15.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $3.77B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-161.73M
TTM Op. Income: $-162.10M
Q. Op. Income: $-45.69M
TTM Net Income: $-152.09M
Q. Net Income: $-43.42M
EPS: $-0.39
Shares Out.: $111.20M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-161.73M and TTM operating income of $-162.10M show growth is flowing through to the bottom line. However, net income is negative at $152.09M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -4569300000.0%
Net Margin: -4342300000.0%

Op. margin of -4569300000.0% is down 283600000.0% YoY — costs are rising relative to revenue. Net margin at -4342300000.0% Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 15.8x

P/S of 0.0x and P/B of 15.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $264.56M
Cash: $49.33M
Long-Term Debt: N/A
Book Value: $239.17M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-31.42M
TTM Free Cash Flow: $-126.72M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-126.72M on $-31.42M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 24% — a weakening trend.